Could vitamin D have a potential anti-inflammatory and anti-infective role in bronchiectasis?

Current Infectious Disease Reports

Volumn 15, Issue 2, 2013, Pages 148-157

  Bartley, Jim ^a   Garrett, Jeff ^a   Grant, Cameron C ^a   Camargo Jr , Carlos A ^b  

^a UNIVERSITY OF AUCKLAND   (New Zealand)

^b MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

Adaptive immunity; Antimicrobial peptides; Bronchiectasis; Chronic rhinosinusitis; Inflammation; Innate immunity; Microbiotia; Obstructive lung disease; Pathology; Pathophysiology; Vitamin D

Indexed keywords

BUDESONIDE; COLECALCIFEROL; PLACEBO; POLYPEPTIDE ANTIBIOTIC AGENT;

ADAPTIVE IMMUNITY; ANTIGEN PRESENTATION; ANTIINFLAMMATORY ACTIVITY; ANTIMICROBIAL ACTIVITY; ARTICLE; B LYMPHOCYTE; BRONCHIECTASIS; DISEASE EXACERBATION; DISEASE SEVERITY; HELPER CELL; HUMAN; INFLAMMATION; INNATE IMMUNITY; LUNG FUNCTION; MICROFLORA; OUTCOME ASSESSMENT; PEPTIDE SYNTHESIS; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL (TOPIC); REGULATORY T LYMPHOCYTE; RESPIRATORY TRACT INFECTION; RISK FACTOR; SINGLE DRUG DOSE; T LYMPHOCYTE; VITAMIN BLOOD LEVEL; VITAMIN D DEFICIENCY; VITAMIN SUPPLEMENTATION;

EID: 84877921883     PISSN: 15233847     EISSN: 15343146     Source Type: Journal    
DOI: 10.1007/s11908-013-0321-9     Document Type: Article

References (101)

1. Hewison M. An update on vitamin D and human immunity. Clin Endocrinol (Oxf). 2012;76:315-25. An excellent recent review of the role of vitamin D in human immunity.
2. Chishimba L, Thickett DR, Stockley RA, et al. The vitamin D axis in the lung: a key role for vitamin D-binding protein. Thorax. 2010;65:456-62.
3. Chalmers J, McHugh B, Docherty C, et al. Vitamin-D deficiency is associated with chronic bacterial colonisation and disease severity in bronchiectasis. Thorax 2013;68:39-47. Recent case series documenting the association of low 25(OH)D levels with bronchiectasis and bronchiectasis severity.
4. Camargo Jr CA, Ganmaa D, Frazier A, et al. Randomized trial of vitamin D supplementation and risk of acute respiratory infection in Mongolia. Pediatrics. 2012;130:e561-7. A well-designed RCT showing a halving in incidence of upper respiratory tract infection in vitamin D deficient children given daily vitamin D supplementation.
5. Urashima M, Segawa T, Okazaki M, et al. Randomized trial of vitamin D supplementation to prevent seasonal influenza A in schoolchildren. Am J Clin Nutr. 2010;91:1255-60.
6. Manaseki-Holland S, Qader G, Isaq Masher M, et al. Effects of vitamin D supplementation to children diagnosed with pneumonia in Kabul: a randomised controlled trial. Trop Med Int Health. 2010;15:1148-55.
7. Coussens A, Wilkinson R, Hanifa Y, et al. Vitamin D accelerates resolution of inflammatory responses during tuberculosis treatment. Proc Natl Acad Sci USA. 2012;109:15449-54. An important clinical study documenting the anti-inflammatory actions of vitamin D in a clinical situation.
8. Institute of Medicine. Dietary reference intakes for calcium and vitamin D. Washington, DC: The National Academies Press; 2010.
9. Bradley JM, Moran F, Greenstone M. Physical training for bronchiectasis. Cochrane Database Syst Rev. 2002;3:CD002166.
10. Kapur N, Bell S, Kolbe J, et al. Inhaled steroids for bronchiectasis. Cochrane Database Syst Rev. 2009;1:CD000996.
11. Lasserson T, Holt K, Greenstone M. Oral steroids for bronchiectasis (stable and acute exacerbations). Cochrane Database Syst Rev. 2001;4:CD002162.
12. Pizzutto SJ, Upham JW, Yerkovich ST, et al. Inhaled non-steroid anti-inflammatories for children and adults with bronchiectasis. Cochrane Database Syst Rev. 2010;4:CD007525.
13. Wong C, Jayaram L, Karalus N, et al. Azithromycin for prevention of exacerbations in non-cystic fibrosis bronchiectasis (EMBRACE): a randomised, double-blind, placebo-controlled trial. Lancet. 2012;380:660-7. Azithromycin appears an important antibiotic in bronchiectasis management.
14. Pincikova T, Nilsson K, Moen IE, et al. Inverse relation between vitamin D and serum total immunoglobulin G in the Scandinavian Cystic Fibrosis Nutritional Study. Eur J Clin Nutr. 2011;65:102-9.
15. King P. The pathophysiology of bronchiectasis. Int J Chron Obstruct Pulmon Dis. 2009;4:411-9.
16. Holick MF. Vitamin D, deficiency. N Eng J Med. 2007;357:266-81.
17. Carlberg C, Molnar F. Current status of vitamin D signaling and its therapeutic applications. Curr Top Med Chem. 2012;12:528-47.
18. Zasloff M. Antimicrobial peptides of multicellular organisms. Nature. 2002;415:389-95.
19. Kim ST, Cha HE, Kim DY, et al. Antimicrobial peptide LL-37 is upregulated in chronic nasal inflammatory disease. Acta Otolaryngol. 2003;123:81-5.
20. Bals R, Wang X, Zasloff M, et al. The peptide antibiotic LL-37/hCAP-18 is expressed in epithelia of the human lung where it has broad antimicrobial activity at the airway surface. Proc Natl Acad Sci U S A. 1998;95:9541-6.
21. Gudmundsson GH, Agerberth B. Neutrophil antibacterial peptides, multifunctional effector molecules in the mammalian immune system. J Immunol Methods. 1999;232:45-54.
22. Brogden KA. Antimicrobial peptides: pore formers or metabolic inhibitors in bacteria? Nat Rev Microbiol. 2005;3:238-50.
23. Rockett KA, Brookes R, Udalova I, et al. 1,25-Dihydroxyvitamin D3 induces nitric oxide synthase and suppresses growth of Mycobacterium tuberculosis in a human macrophage-like cell line. Infect Immun. 1998;66:5314-21.
24. Desjardins M, Huber LA, Parton RG, et al. Biogenesis of phagolysosomes proceeds through a sequential series of interactions with the endocytic apparatus. J Cell Biol. 1994;124:677-88.
25. Russell DG. Mycobacterium and Leishmania: stowaways in the endosomal network. Trends Cell Biol. 1995;5:125-8.
26. Pieters J. Evasion of host cell defense mechanisms by pathogenic bacteria. Curr Opin Immunol. 2001;13:37-44.
27. Hmama Z, Sendide K, Talal A, et al. Quantitative analysis of phagolysosome fusion in intact cells: inhibition by mycobacterial lipoarabinomannan and rescue by an 1alpha,25-dihydroxyvitamin D3-phosphoinositide 3-kinase pathway. J Cell Sci. 2004;15:2131-40.
28. Coussens A, Timms PM, Boucher BJ, et al. 1alpha,25-dihydroxyvitamin D3 inhibits matrix metalloproteinases induced by Mycobacterium tuberculosis infection. Immunology. 2009;127:539-48.
29. Adorini L, Penna G. Dendritic cell tolerogenicity: a key mechanism in immunomodulation by vitamin D receptor agonists. Hum Immunol. 2009;70:345-52.
30. Steinman RM, Banchereau J. Taking dendritic cells into medicine. Nature. 2007;449:419-26.
31. Mahnke K, Johnson TS, Ring S, et al. Tolerogenic dendritic cells and regulatory T cells: a two-way relationship. J Dermatol Sci. 2007;46:159-67.
32. Medzhitov R, Janeway Jr C. Innate immunity. N Engl J Med. 2000;343:338-44.
33. Margulies DH. TCR avidity: it's not how strong you make it, it's how you make it strong. Nat Immunol. 2001;2:669-70.
34. Slifka MK, Whitton JL. Functional avidity maturation of CD8(+) T cells without selection of higher affinity TCR. Nat Immunol. 2001;2:711-7.
35. Lemire JM, Archer DC, Beck L, et al. Immunosuppressive actions of 1,25-dihydroxyvitamin D3: preferential inhibition of Th1 functions. J Nutr. 1995;125(6 Suppl):1704S-8.
36. Chambers ES, Hawrylowicz CM. The impact of vitamin D on regulatory T cells. Curr Allergy Asthma Rep. 2011;11:29-36.
37. Vignali DAA, Collison LW, Workman CJ. How regulatory T cells work. Nat Review Immunol. 2008;8:523-32.
38. Jeffery LE, Burke F, Mura M, et al. 1,25-Dihydroxyvitamin D3 and IL-2 combine to inhibit T cell production of inflammatory cytokines and promote development of regulatory T cells expressing CTLA-4 and FoxP3. J Immunol. 2009;183:5458-67.
39. Chen S, Sims GP, Chen XX, et al. Modulatory effects of 1,25-dihydroxyvitamin D3 on human B cell differentiation. J Immunol. 2007;179:1634-47.
40. Dimeloe S, Nanzer A, Ryanna K, et al. Regulatory T cells, inflammation and the allergic response - The role of glucocorticoids and Vitamin D. J Steroid Biochem Mol Biol. 2010;120:86-95.
41. Jirapongsananuruk O, Melamed I, Leung DY. Additive immunosuppressive effects of 1,25(OH)2D3 and corticosteroids on Th1, but not Th2, responses. J Allergy Clin Immunol. 2000;106:981-5.
42. Pichler J, Gerstmayr M, Szepfalusi Z, et al. 1 alpha,25(OH)2D3 inhibits not only Th1 but also Th2 differentiation in human cord blood T cells. Pediatr Res. 2002;52:12-8.
43. Rothers J, Wright A, Halonen M, et al. Cord blood 25-hydroxyvitamin D levels are associated with aeroallergen sensitization in children from Tucson, Arizona. J Allergy Clin Immunol. 2011;128:1093-9. This article has shown that both high and low 25-hydroxyvitamin D levels are associated with aeroallergen sensitization.
44. Dunne Jr WM. Bacterial adhesion: seen any good biofilms lately? Clin Microbiol Rev. 2002;15:155-66.
45. Otto M. Bacterial evasion of antimicrobial peptides by biofilm formation. Curr Top Microbiol Immunol. 2006;306:251-8.
46. Schmidtchen A, Frick I-M, Andersson E, et al. Proteinases of common pathogenic bacteria degrade and inactivate the antibacterial peptide LL-37. Mol Microbiol. 2002;46:157-68.
47. Rosenfeld Y, Shai Y. Lipopolysaccharide (Endotoxin)-host defense antibacterial peptides interactions: role in bacterial resistance and prevention of sepsis. Biochim Biophys Acta. 2006;1758:1513-22.
48. Overhage J, Campisano A, Bains M, et al. Human host defense peptide LL-37 prevents bacterial biofilm formation. Infect Imm. 2008;76:4176-82.
49. Chennupati SK, Chiu AG, Tamashiro E, et al. Effects of an LL-37-derived antimicrobial peptide in an animal model of biofilm Pseudomonas sinusitis. Am J Rhinol Allergy. 2009;23:46-51.
50. Matheson EM, Mainous 3rd AG, Hueston WJ, et al. Vitamin D and methicillin-resistant Staphylococcus aureus nasal carriage. Scand J Infect Dis. 2010;42:455-60.
51. Olsen K, Falch BM, Danielsen K, et al. Staphylococcus aureus nasal carriage is associated with serum 25-hydroxyvitamin D levels. Eur J Clin Microbiol Infect Dis. 2012;31:465-73.
52. Eastham KM, Freeman R, Kearns AM, et al. Clinical features, aetiology and outcome of empyema in children in the north east of England. Thorax. 2004;59:522-5.
53. Pasteur MC, Helliwell SM, Houghton SJ, et al. An investigation into causative factors in patients with bronchiectasis. Am J Resp Crit Care Med. 2000;162:1277-84.
54. Kolbe J, Wells A. Bronchiectasis: a neglected cause of respiratory morbidity and mortality. Respirology. 1996;1:221-5.
55. Roberts HJ, Hubbard R. Trends in bronchiectasis mortality in England and Wales. Respir Med. 2010;104:981-5.
56. Seitz AE, Olivier KN, Steiner CA, et al. Trends and burden of bronchiectasis-associated hospitalizations in the United States, 1993-2006. Chest. 2010;138:944-9.
57. Field CE. Bronchiectasis. A long-term follow-up of medical and surgical cases from childhood. Arch Dis Child. 1961;36:587-603.
58. Twiss J, Metcalfe R, Edwards E, et al. New Zealand national incidence of bronchiectasis "too high" for a developed country. Arch Dis Child. 2005;90:737-40.
59. Haidopoulou K, Calder A, Jones A, et al. Bronchiectasis secondary to primary immunodeficiency in children: longitudinal changes in structure and function. Pediatr Pulmonol. 2009;44:669-75.
60. Eastham KM, Fall AJ, Mitchell L, et al. The need to redefine non-cystic fibrosis bronchiectasis in childhood. Thorax. 2004;59:324-7.
61. Courtney J, Kelly M, Watt A, et al. Quality of life and inflammation in exacerbations of bronchiectasis. Chron Respir Dis. 2008;5:161-8.
62. Dupont M, Gacouin A, Lena H, et al. Survival of patients with bronchiectasis after the first ICU stay for respiratory failure. Chest. 2004;125:1815-20.
63. Singleton R, Morris A, Redding G, et al. Bronchiectasis in Alaska Native children: causes and clinical courses. Pediatr Pulmonol. 2000;29:182-7.
64. Roberts ME, Lowndes L, Milne DG, et al. Socioeconomic deprivation, readmissions, mortality and acute exacerbations of bronchiectasis. Intern Med J. 2012;42:e129-36.
65. Roberts H, Wells A, Milne D, et al. Airflow obstruction in bronchiectasis: correlation between computed tomography features and pulmonary function tests. Thorax. 2000;55:198-204.
66. Gaga M, Bentley AM, Humbert M, et al. Increases in CD4+ T lymphocytes, macrophages, neutrophils and interleukin 8 positive cells in the airways of patients with bronchiectasis. Thorax. 1998;53:685-91.
67. Barker AF. Bronchiectasis. N Engl J Med. 2002;346:1383-93.
68. Zheng L, Tipoe G, Lam W, et al. Endothelin-1 in stable bronchiectasis. Eur Respir J. 2000;16:146-9.
69. Tsang KW, Chan K, Ho P, et al. Sputum elastase in steady-state bronchiectasis. Chest. 2000;117:420-6.
70. Richman-Eisenstat JB, Jorens PG, Hebert CA, et al. Interleukin-8: an important chemoattractant in sputum of patients with chronic inflammatory airway diseases. Am J Physiol. 1993;264:L413-8.
71. Shum DK, Chan SC, Ip MS. Neutrophil-mediated degradation of lung proteoglycans: stimulation by tumor necrosis factor-alpha in sputum of patients with bronchiectasis. Am J Resp Crit Care Med. 2000;162:1925-31.
72. Wilson R, Cole PJ. The effect of bacterial products on ciliary function. Am Rev Resp Dis. 1988;138:S49-53.
73. Beck JM, Young VB, Huffnagle GB. The microbiome of the lung. Transl Res. 2012;160:258-66. An important review article about a rapidly evolving area of microbiology.
74. Charlson ES, Bittinger K, Haas AR, et al. Topographical continuity of bacterial populations in the healthy human respiratory tract. Am J Resp Crit Care Med. 2011;184:957-63.
75. Hare KM, Grimwood K, Leach AJ, et al. Respiratory bacterial pathogens in the nasopharynx and lower airways of Australian indigenous children with bronchiectasis. J Pediatr. 2010;157:1001-5.
76. Godoy JM, Godoy AN, Ribalta G, et al. Bacterial pattern in chronic sinusitis and cystic fibrosis. Otolaryngol Head Neck Surg. 2011;145:673-6.
77. Guilemany JM, Angrill J, Alobid I, et al. United airways: the impact of chronic rhinosinusitis and nasal polyps in bronchiectasic patient's quality of life. Allergy. 2009;64:1524-9.
78. Bardin P, Van Heerden B, Joubert J. Absence of pulmonary aspiration of sinus contents in patients with asthma and sinusitis. J Allergy Clin Immunol. 1990;86:82-3.
79. Brehm J, Schuemann B, Fuhlbrigge A, et al. Serum vitamin D levels and severe asthma exacerbations in the childhood asthma management program study. J Allergy Clin Immunol. 2010;126:52-8.
80. Brehm JM, Acosta-Perez E, Klei L, et al. Vitamin D insufficiency and severe asthma exacerbations in Puerto Rican children. Am J Resp Crit Care Med. 2012;186:140-6.
81. Lehouck A, Mathieu C, Carremans C, et al. High doses of vitamin D to reduce exacerbations in chronic obstructive pulmonary disease: a randomized trial. Ann Intern Med. 2012;156:105-14.
82. Bartley J, Camargo CA Jr. Vitamin D and infection. In: Vitamin D: oxidation, immunity & aging. Edited by Gombart A. Taylor & Francis Group, CRC Press; 2012:323-48. A recent review of clinical studies investigating the role of vitamin D in infectious disease.
83. Majak P, Olszowiec-Chlebna M, Smejda K, et al. Vitamin D supplementation in children may prevent asthma exacerbation triggered by acute respiratory infection. J Allergy Clin Immunol. 2011;127:1294-6.
84. Manaseki-Holland S, Maroof Z, Bruce J, et al. Effect on the incidence of pneumonia of vitamin D supplementation by quarterly bolus dose to infants in Kabul: a randomised controlled superiority trial. Lancet. 2012;379:1419-27.
85. Martineau AR, Timms PM, Bothamley GH, et al. High-dose vitamin D3 during intensive-phase antimicrobial treatment of pulmonary tuberculosis: a double-blind randomised controlled trial. Lancet. 2011;377:242-50.
86. Murdoch D, Slow S, Chambers S, et al. Effect of vitamin D3 supplementation on upper respiratory infections in healthy adults: A randomised, double blind, placebo-controlled trial. JAMA. 2012;308:1333-9. A recent RCT indicating that vitamin D levels above 75nmol/L may not provide protection against upper respiratory infection.
87. Nielsen NO, Skifte T, Andersson M, et al. Both high and low serum vitamin D concentrations are associated with tuberculosis: a case-control study in Greenland. Br J Nutr. 2010;104:1487-91.
88. Martineau AR. Bolus-dose vitamin D and prevention of childhood pneumonia. Lancet. 2012;379:1373-5.
89. Stephenson A, Brotherwood M, Robert R, et al. Cholecalciferol significantly increases 25-hydroxyvitamin D concentrations in adults with cystic fibrosis. Am J Clin Nutr. 2007;85:1307-11.
90. Grossmann RE, Zughaier SM, Kumari M, et al. Pilot study of vitamin D supplementation in adults with cystic fibrosis pulmonary exacerbation: A randomized, controlled trial. Dermatoendocrinol. 2012;4:191-7.
91. Grossmann RE, Zughaier SM, Liu S, et al. Impact of vitamin D supplementation on markers of inflammation in adults with cystic fibrosis hospitalized for a pulmonary exacerbation. Eur J Clin Nutr. 2012;66:1072-4.
92. Reid D, Toole B, Knox S, et al. The relation between acute changes in the systemic inflammatory response and plasma 25-hydroxyvitamin D concentrations after elective knee arthroplasty. Am J Clin Nutr. 2011;93:1006-11.
93. Bischoff-Ferrari HA, Giovannucci E, Willett WC, et al. Estimation of optimal serum concentrations of 25-hydroxyvitamin D for multiple health outcomes. Am J Clin Nutr. 2006;84:18-28.
94. Calverley P, Pauwels Dagger R, Lofdahl C, et al. Relationship between respiratory symptoms and medical treatment in exacerbations of COPD. Eur Respir J. 2005;26:406-13.
95. Murray MP, Turnbull K, MacQuarrie S, et al. Validation of the Leicester Cough Questionnaire in non-cystic fibrosis bronchiectasis. Eur Resp J. 2009;34:125-31.
96. Eaton T, Young P, Fergusson W, et al. The Dartmouth COOP Charts: a simple, reliable, valid and responsive quality of life tool for chronic obstructive pulmonary disease. Qual Life Res. 2005;14:575-85.
97. Djukanovic R, Sterk P, Fahy J, et al. Standardised methodology of sputum induction and processing. Eur Resp J. 2002;37:1s-2.
98. Aloia JF, Li-Ng M. Re: epidemic influenza and vitamin D. Epidemiol Infect. 2007;135:1095-6. author reply 7-8.
99. Avenell A, Cook JA, Maclennan GS, et al. Vitamin D supplementation to prevent infections: a sub-study of a randomised placebo-controlled trial in older people (RECORD trial, ISRCTN 51647438). Age Ageing. 2007;36:574-7.
100. Li-Ng M, Aloia JF, Pollack S, et al. A randomized controlled trial of vitamin D3 supplementation for the prevention of symptomatic upper respiratory tract infections. Epidemiol Infect. 2009;137:1396-404.
101. Laaksi I, Ruohola JP, Mattila V, et al. Vitamin D supplementation for the prevention of acute respiratory tract infection: a randomized, double-blinded trial among young Finnish men. J Inf Dis. 2010;202:809-14.